Skip to content

Carrying Clinical Evidence into the Regulatory Submission

At AIDDD 2026, AlphaLife Sciences explored how teams can preserve the evidence and context behind clinical results as they move into a regulatory submission.

Post-event banner for the 2026 AI Drug Discovery & Development Summit in Boston

The AI Drug Discovery & Development Summit brought researchers, data scientists, and clinical development teams to the Boston Marriott Copley Place on October 27–29, 2026. Its agenda spanned discovery biology and chemistry, data management and infrastructure, clinical trials, and technology operations. At Booth 24, AlphaLife Sciences focused on the downstream work of explaining clinical evidence in the documents that make up an electronic Common Technical Document (eCTD) submission. See the summit agenda and our event page.

The clinical trials program covered AI applications in trial design, patient recruitment, and study execution. The data program addressed how teams bring together information held in separate systems. Those topics raise a related question for medical writers. When a development team passes a result to the people preparing the submission, can they still see who was included, how the outcome was measured, and which analysis produced it? That context shapes what a writer can say about the result and what a reviewer can verify.

Carry the study context forward with the result

A clinical summary may bring together results from studies with different analysis populations or assessment schedules. When a finding moves from a clinical study report into that summary, the writer needs the context that makes the comparison meaningful. For example, a numerical difference between studies can look straightforward until the reviewer sees that the assessments took place at different time points.

Consider a response rate measured at week 12 in one study and week 24 in another. If the summary gives the two percentages side by side, it should make the time points clear. The reviewer may also need to know whether both analyses included the same types of participants and how each handled missing assessments. Those details help the team decide whether to present the findings together and how to describe any apparent difference.

That is a practical use for source-linked authoring. A writer can draft the summary with access to the underlying report and evidence, then check that the new wording preserves the conditions under which the result was observed.

The wording may differ across documents. A study report can explain the analysis in detail, while a clinical summary may need only enough context to support a cross-study comparison. A reference to the specific table or report section gives the reviewer a way to check that the shorter wording still supports the intended interpretation.

Make the next revision easier to assess

If the source result is updated, connected authoring can help identify passages across the dossier that refer to it. Reviewers can then decide whether each passage needs a revised figure, a different interpretation, or an explanation of how it relates to the other studies. Recording those decisions helps downstream reviewers understand how the submission took shape.

Suppose a later data cutoff changes the number of participants included in an analysis. The figure in the clinical summary may change, and a sentence in the clinical overview may need a fresh assessment. A separate passage may still describe the earlier cutoff for a valid reason. Reviewing those passages against the relevant report versions helps the team decide where an edit is needed and where the historical context belongs.

Follow one result through the submission

A team evaluating this workflow can start with one result that appears in both a study report and a clinical summary. Ask the writer to trace the summary sentence back to its table, verify the analysis population and time point, and check which other passages use the same result. Then review a later version of the report and record the reasons for each downstream edit. That exercise shows where connected authoring can support the team’s existing review process.

Thank you to the AIDDD community for bringing discovery and development teams together. Explore AuroraPrime RMA for regulatory authoring.

Close